# Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

> **NCT03266692** · PHASE1 · TERMINATED · sponsor: **Cogent Biosciences, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma
- Multiple Myeloma in Relapse
- Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ACTR087
- **BIOLOGICAL:** SEA-BCMA

## Key facts

- **NCT ID:** NCT03266692
- **Lead sponsor:** Cogent Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-22
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-10-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2020-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03266692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03266692, "Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03266692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*